Israeli "digital X-ray" company Nanox is fielding increased scrutiny and a sizable hit to its share prices following the publication of a scathing report and commentary that referred to the company as "Theranos 2.0."
The criticism was posted yesterday by activist short seller Andrew Left's Citron Research, an online stock analysis and commentary blog that has focused on identifying overpriced or...
